KRAS P.G12C
9 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation (NCT05288205) | Allist Pharmaceuticals, Inc. | 2022-04-14 |
| Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy (NCT05398094) | Fundación GECP | 2022-03-21 |
| RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC (NCT05273047) | Intergroupe Francophone de Cancerologie Thoracique | 2022-03-01 |
Track KRAS P.G12C automatically
Every clearance here is in the API, with alerts when new ones post.